Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB–III cutaneous melanoma (CM) patients (pts) after surgery in an open, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mordoh, José, Pampena, María Betina, Aris, Mariana, Blanco, Paula Alejandra, Lombardo, Mónica, von Euw, Erika María, Mac Keon, Soledad, Yépez Crow, Michelle, Bravo, Alicia Inés, O’Connor, Juan Manuel, Orlando, Ana Gabriela, Ramello, Franco, Levy, Estrella Mariel, Barrio, María Marcela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449770/
https://www.ncbi.nlm.nih.gov/pubmed/28620382
http://dx.doi.org/10.3389/fimmu.2017.00625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449770/
https://www.ncbi.nlm.nih.gov/pubmed/28620382
http://dx.doi.org/10.3389/fimmu.2017.00625

Ejemplares similares